Meeting
2023 ASCO Annual Meeting
H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.
Authors
Yang Zhang
Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Yang Zhang , Nan Ji , Gang Chen , Haiyang Wu , Yi Wang , Xiao’ou Li , Ling Peng , Wei Xu , Tian Li , Yi Wang , Li-Feng Zhang , Shengjun Sun , Xiaobin Zhao , Si Li , Frank Su , Qi-Jing Li , Liwei Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04749641
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2052)
DOI
10.1200/JCO.2023.41.16_suppl.2052
Abstract #
2052
Poster Bd #
409
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.
First Author: Aaron Miller
Poster
2013 ASCO Annual Meeting
Phase I study of peptide vaccine targeting indeolamine 2,3 dioxygenase in metastatic lung cancer patients.
First Author: Trine Zeeberg Iversen
Poster
2023 ASCO Annual Meeting
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
First Author: Sofie Kirial Mørk
Poster
2022 ASCO Annual Meeting
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).
First Author: Jean-Pierre Delord